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Summary 
Thyrotropin releasing hormone is thought to be a tonic stimu- 
lator of the pituitary TSH secretion regulating the setpoint of the 
thyrotrophs to he suppressive effect of thyroid hormones. The 
peptide stimulates the release of normal and elevated prolactin. 
ACTH and GH may increase in response to exogenous TRH in 
pituitary ACTH and GH hypersecretion syndromes and in some 
extrapituitary diseases. 
The pathophysiological imp ications ofextrahypothalamic TRH 
in humans are essentially unknown. 
The TSH response to TRH is nowadays widely used as a 
diganostic amplifier in thyroid diseases being suppressed in border- 
line and overt hyperthyroid states and increased inprimary thyroid 
failure. In hypothyroid states of hypothalamic origin, TSH increases 
in response to exogenous TRH often with a delayed and/or 
exaggerated time course. 
But in patients with pituitary tumors and suprasellar extension 
TSH may also respond to TRH despite secondary hypothyroidism. 
This TSH increase may indicate a suprasellar cause for the secondary 
hypothyroidism, probably due to portal vessel occlusion. The TSH 
released in these cases is hown to be biologically inactive. 
Keywords: TRH; diagnostic significance; hypothalamic diseases; 
pituitary failure. 
TRH,  initially detected and synthesized as the 
hypothalamic hormone that controls the thyrotrophic 
activity was found to stimulate the prolactin release in 
vivo and in vitro 43, 45, 63, 72, 77 Moreover, TRH has been 
shown to be widely distributed over the central nervous 
system36, 3v, 44, 71, where it is believed to have neuro- 
transmitter functions besides the hypophysiotropic 
effects. 
TRH has been detected in the upper gastrointestinal 
tract 14, where its endogenous functions are unknown. 
Exogenous TRH inhibits the pentagastrin stimulated 
gastric secretion 12 and by some degree the glucagon 
and pancreatic polypeptide release after insulin induced 
hypoglycemia 13. 
TRH and Thyrotropie Activity 
Experimental and pathological disruption of the 
hypothalamic supply of the pituitary with TRH results 
in decreased thyroid function 47, called secondary hypo- 
thyroidism. TRH antibodies induce impairment of 
thyroid function with some effects on the prolactin 
secretion as well 28, 32, 39, 76. But until now, there are no 
consistent data on the physiological hypothalamo- 
pituitary relationship in humans. This is due to the fact 
that serum and urinary TRH is mainly derived from 
extrahypothalamic sources 46. In experimental hypo- 
and hyperthyroidism the hypothalamic ontent of 
TRH does not change 52 arguing against a feedback 
inhibition between TRH and TSH. There are few 
studies reporting a decrease of TRH in hyper- and an 
increase in hypothyroidism with marked differences in 
the reported normal evels 29, 50. Most authors postulate 
today that TRH is a tonic stimulator of the TSH 
secretion, modulating the set point of the thyrotrophs 
to the suppressive ffect of thyroid hormones 47. 
TSH responses to TRH are modulated by estrogens 
in females and in males 2o. This modulation is due to 
increasing binding sites of pituitary cells under estrogen 
influence which can be partly antagonized by thyroid 
hormones  42. 
Repetitive intravenous and chronical oral TRH 
administration in euthyroid and hypothyroid indi- 
viduals results in a decrease of serum TSH 1,4, 34, 38, 62, 75 
and in euthyroids in an increase of thyroid hormones 
within the upper normal range 3, 34, 62 The TSH 
decrease following TRH administration was also ob- 
served in athyroid patients 75. The latter finding may be 
suggestive for down regulation of the TRH receptor of 
the thyrotrophs which is transient 62, or for a predomi- 
nant stimulation of TSH release and a slower de novo 
synthesis of pituitary TSH 38. The simultaneous de- 
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crease of PRL under these conditions was more 
pronounced 51. 
The thyrotropic activity is under an inhibitory 
control of somatostatin 78 and dopamine 5,11, 27, 48, 63, 66, 
which is more evident in euthyroids, mild and treated 
hypothyroidism than in severe hypothyroidism , 25 
Dopamine modulates the diurnal variations of 
TSH67, 74. In states with increased hypothalamic 
dopamine turnover the tonic inhibition of TSH is 
thought o be enhanced 68. This seems to have no 
clinical implications since oral treatment with 
dopamine agonists 4~ and antagonists 81 does not in- 
fluence TSH levels and TSH response to TRH. 
TRH and Other Pituitary Hormones 
In normal adults TRH does not influence the release 
of GH and ACTH 53. In states with borderline or overt 
functional disturbances of the GH producing cells, such 
as active acromegaly 82, 83, children with constitutional 
tall stature and elevated somatomedin levels a7 and in 
type I diabetes, predominantly in females 7 and in 
newborns, when TRH was administered to the mother 
shortly before delivery 64, TRH may stimulate GH 
release. In addition, TRH reduces the somatostatin 
induced inhibition f GH release in vitro 16. 
TRH stimulates prolactin release in normal, hyper- 
and hypothyroid ndividuals 43, 45, 63. Elevated prolactin 
levels have been observed in patients with primary 
hypothyroidism and can be lowered by thyroid 
hormones. In hyperthyroidism mean prolactin levels 
are lower as compared to normals and increase during 
antithyroid treatment 72. Recently, specific inhibition 
of prolactin synthesis (decrease ofPRL m RNA) by T 3 
in vitro was shown 49. 
In normals prolactin is mainly under the inhibitory 
hypothalamic control and the observed modulation of 
prolactin secretion by TRH gain clinical significance 
only in severe hypothyroidism. 
In prolactinomas the TRH induced prolactin in- 
crease is low with high basal evels of prolactin and vice 
versa 26. 
In patients with Cushing's disease 61 TRH may 
induce a paradoxical rise of ACTH. 
Thus, TRH like GnRH may be recognized as a 
stimulator by non thyrotropic pituitary ceils under 
pathological conditions. 
Modulation of the TSH Response to TRH by Non- 
thyroidal Endocrine and Non-Endocrine Diseases 
The TSH response to TRH is nowadays widely used 
as a diagnostic tool in thyroidology. Therefore, it was 
necessary to evaluate factors and hormones which 
modulate the TSH response innon-thyroidal endocrine 
and non-endocrine diseases. 
In Cushing's syndrome irrespective of the pathogen- 
esis and during gtucocorticosteroid pharmacotherapy 
basal TSH and TSH response may be blunted or 
suppressed21, 41,54, 73, 84, and return to normal after 
successful treatment ofhypercortisolism. In Addison's 
disease moderately elevated basal TSH levels have been 
observed 3.
In patients with active acromegaly blunted TSH 
response to TRH has been reported 10, 82 and TSH 
response may be elevated in GH deficiency i0
Recently, diminished TSH stimulation has been 
reported in chronic hypercalcemia and a pronounced 
increase in hypoparathyroid individuals 33, variations 
which return to normal after correction of serum 
calcium levels. 
There is an increasing number of data on decreased 
TSH response to TRH in patients with severe non- 
thyroidal illness and during total fasting 35, 7o. The 
pathogenesis of these disturbances in the TSH re- 
sponsiveness ofthe pituitary is not yet well understood. 
Patients do not exhibit clinical signs of hypothyroidism 
despite the concomittant development ofconsiderable 
alterations in the peripheral thyroid hormone metab- 
Olism: These phenomena were recently reviewed 8~ 
These modulations of the TSH response to TRH in 
endocrine and non-endocrine diseases have to be kept 
in mind when using the TRH-test for clinical purposes. 
TRH Test in Diagnosis of Hypothalamic and Pituitary 
Diseases 
When TRH became available for clinical investiga- 
tions, the TRH-test was expected to differentiate 
between hypothalamic and pituitary origin of central 
hypothyroidism. Patients with hypothyroidism of obvi- 
ous hypothalamic origin were shown to have the 
expected response of TSH to TRH 31, 56, 58, 69, which is 
often delayed and or exaggerated 19,22, 23 
But patients with pituitary tumors, suprasellar 
extension and visual field impairment exhibited an 
unexpected TSH response to TRH 19, 56 which is often 
delayed and exaggerated as well. The net increment of 
TSH may not differ from normals or from euthyroid 
patients with pituitary tumors (Fig. 1). 
In none of our patients the TSH-response to TRH 
was completely absent before pituitary surgery and 
only in some of them postoperatively 56, 57. 
Similar data were reported from other groups 19, 31, 
55 Thus, the failure of TRH test to differentiate 
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between hypothalamic and pituitary insufficiency was 
documented. 
These findings allow at least two hypothetical 
explanations. From our data in patients with large 
pituitary tumors we suggested, that the increase of TSH 
levels after TRH indicates a suprasellar cause of
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Fig. 1. TSH-response to TRH in patients with pituitary tumors. The 
upper panel depicts the TSH-response to TRH in 11 euthyroid 
patients, in the lower panel the TSH-response in 9 hypothyroid 
patients i demonstrated 
secondary hypothyroidism, probably due to a partial 
occlusion of the portal vessel system, thus preventing 
the endogenous TRH from reaching the remaining 
pituitary thyrotrophs 56, 57, 58, 69. This explanation was 
picked up very recently for the recovery of partial 
pituitary insufficiency after treatment of large inactive 
pituitary tumors 2 and for a moderate increase in PRL 
levels after irradiation of the pituitary in acromegaly 9. 
Faglia and coworkers initially postulated the secre- 
tion of a biologically inactive TSH 19. In further 
investigations they documented an impaired T 3 in- 
crease after TRH induced elevation of the TSH levels 22 
and diminished biological activity of the TSH in a 
cytochemical bioassay despite immunoidentity to 
standard TSH 23. More recently, the group published 
the observation of an elevated ratio of 13 TSH to a TSH 
subunit in idiopathic entral hypothyroidism 2~. Oral 
treatment with TRH in one patient resulted in a 
decrease of the [3/ct ratio and his thyroid became 
responsive to the endogenous TRH-stimulated TSH. 
The authors conclude that TRH may be imperative in 
the secretion of TSH with full biological potency. 
TRH Test as a Thyroid Function Test 
In euthyroid men basal TSH levels as measured by 
radioimmunoassay re undetectable in about 30%. 
Thus, by means of basal TSH one can ot distinguish 
suppressed TSH secretion from normal. Therefore, 
TRH-unresponsiveness of TSH offers more informa- 
tion. The test is nowadays used as an amplifyer in cases 
of borderline hyperthyroidism in "euthyroid" Graves' 
disease before and after treatment, in cases with 
autonomous functioning solitary and multiple adeno- 
mas and in nodular goiters 30. Using the TRH test for 
routine purposes itbecame obvious that in our hospital 
population in 446 patients observed over a period of 12 
months TSH suppression was due to preclinical hyper- 
thyroidism in 88 (20)%. Out of these about 44% were 
iodine contaminated. In our area with nutritional 
iodine deficiency, endemic goiter and an increased 
prevalence of autonomous adenomas, patients at risk 
for hyperthyroidism are more easily detected by TRH- 
test as compared to investigations of the peripheral 
thyroid hormone levels alone. In this context it may be 
of interest that in the course of longterm treatment with 
the anfiarhythmic drug Amiodarone about 30% of 
bavarian patients developed preclinical hyper- 
thyroidism 6~ 
By the combination of TRH stimulation test and the 
scinti-scans autonomous adenoma 59 can be classified 
into different groups depending on the extent of TSH 
suppression. For economical reasons ome European 
investigators u e the test as a first step diagnostic tool. 
In primary thyroid failure exaggerated TSH- 
response may indicate earlier thyroid insufficiency, 
undetectable by clinical signs, lowered thyroid 
hormones or elevated basal TSH, a situation found in 
about 20% of patients with endemic goiter in this area. 
Therapeutical Aspects 
Experimental investigations of cardiovascular 
function and survival rates in endotoxic shock gave rise 
to the conclusion that TRH administered intravenously 
in high dosages improves the outcome in experimental 
animal models. In addition, Faden and coworkers 
observed a significantly better neurological recovery 
after spine injury in cats 18. They explain these ffects by 
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a par t ia l  op iate  antagon ism of  TRH because s imi lar  
effects occur  dur ing  t reatment  with na loxone.  
In humans ,  TRH was found to improve  atax ia  in 
pat ients  wi th  sp inocerebe l lar  degenerat ion .  Recent ly ,  
Engel  and  coworkers  15 repor ted  marked  improvement  
o f  weakness  and  spast ic i ty  in amyot roph ic  lateral  
sclerosis after  TRH i. v. The just i f i cat ion  for  t reatment  
was der ived f rom the observat ion  in animals ,  where 
TRH has been detected in nerve endings in the ventra l  
horn  o f  lower  motor  neurons  and in nerve endings in 
motor  nuc lear  V, VI I ,  X I I .  In a pre l iminary  s tudy the 
authors  found reduced TRH levels in CSF  o f  pat ients  
with amyot roph ic  lateral  sclerosis and other  spast ic  
diseases. 
Because amyot roph ic  latera l  sclerosis is a pro -  
gressive disease, these observat ions  prompted  us to 
in i t iate a p i lo t  s tudy with ora l  TRH in one pat ient  who 
is present ly  under  invest igat ion.  
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